✦ LIBER ✦

The Immunology of Alzheimer’s Disease: Prospects Towards Harnessing Disease Mechanisms for Therapeutic Ends

✍ Scribed by Landreth, Gary

Book ID: 107380599
Publisher: Springer US
Year: 2007
Tongue: English
Weight: 70 KB
Volume: 2
Category: Article
ISSN: 1557-1890
DOI: 10.1007/s11481-007-9067-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Understanding molecular mechanisms of pr

Understanding molecular mechanisms of proteolysis in Alzheimer's disease: Progress toward therapeutic interventions

✍ Makoto Higuchi; Nobuhisa Iwata; Takaomi C. Saido 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 359 KB

The Development of New Therapeutics for

The Development of New Therapeutics for Alzheimer's Disease

✍ Carter, M D; Simms, G A; Weaver, D F 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 454 KB

Neuroimaging in Alzheimer's Disease: Rel

Neuroimaging in Alzheimer's Disease: Relevance for the Development of Therapeutic Agents

✍ Christopher H. Van Dyck 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 13 KB

The expanding role of BDNF: a therapeuti

The expanding role of BDNF: a therapeutic target for Alzheimer's disease?

✍ Fumagalli, F; Racagni, G; Riva, M A 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 106 KB

PPARγ agonists as therapeutics for the t

PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease

✍ Gary Landreth; Qingguang Jiang; Shweta Mandrekar; Michael Heneka 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 241 KB

Advances in the development of kinase in

Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease

✍ Mary J. Savage; Diane E. Gingrich 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 576 KB

## Abstract Pharmaceutical approaches to slow the progression of Alzheimer's disease (AD) have focused primarily on reducing production or increasing clearance of amyloid β peptide (Aβ). Recent clinical trial results question the efficacy of targeting Aβ for treatment of mild to moderate AD, highli